文献速递膀胱癌与上尿路尿路上皮癌

根治性膀胱切除术前重复经尿道电切治疗肌层浸润性膀胱癌具有预后价值但无治疗获益

Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic.
PubMed 文献 · J Urol · 2022-10-11

在三级医疗中心2005至2017年657例临床T2尿路上皮癌行根治性膀胱切除术患者中,按倾向评分1:1匹配后纳入548例(两组各274例),重复经尿道膀胱肿瘤电切组与未重复组无复发生存和总生存均无显著差异(P=1.0和P=.3)。重复电切标本pT0者较残留肌层浸润者无复发生存和总生存更优(P<.001和P=.001),但超过60%的重复电切pT0患者根治性膀胱切除标本仍有残留病变。

要点

  • 根治性膀胱切除术前重复经尿道膀胱肿瘤电切与未重复者生存无显著差异(P=1.0和P=.3)。
  • 重复电切标本pT0者较残留肌层浸润者无复发生存和总生存更优(P<.001和P=.001)。
  • 超过60%的重复电切pT0患者根治性膀胱切除标本仍有残留病变。

核心结论

  • 根治性膀胱切除术前重复经尿道膀胱肿瘤电切与改善生存结局无关,无论是否接受新辅助化疗。
  • 重复电切标本病理评估无残留肿瘤具有预后价值,与改善生存结局相关。
  • 但重复电切pT0患者中很大比例在根治性膀胱切除病理中仍有残留病变。

研究设计与样本

  • 经机构审查委员会批准的回顾性审查,纳入2005至2017年在本院因临床T2尿路上皮癌行根治性膀胱切除术的657例肌层浸润性膀胱癌患者。
  • 按年龄、性别、接受新辅助化疗、术前肾积水、变异组织学、淋巴血管侵犯或指数经尿道膀胱肿瘤电切标本中的原位癌进行倾向评分1:1匹配。
  • 匹配后共纳入548例肌层浸润性膀胱癌患者(两组各274例)。

主要发现

  • Kaplan-Meier估计的无复发生存和总生存基于是否行重复经尿道膀胱肿瘤电切无显著差异(P=1.0和P=.3)。
  • 重复电切标本pT0者较残留肌层浸润性疾病者无复发生存和总生存更优(P<.001和P=.001)。
  • 超过60%的重复电切pT0患者在根治性膀胱切除时仍有残留病变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to evaluate the impact of repeat transurethral resection of bladder tumor prior to radical cystectomy on oncologic outcomes in a contemporary cohort at a tertiary care center. MATERIALS AND METHODS: An Institutional Review Board approved review of 657 patients diagnosed with muscle-invasive bladder cancer who underwent radical cystectomy at our institution for clinical stage T2 urothelial carcinoma between 2005 and 2017 was performed. Patients with and without repeat transurethral resection of bladder tumor were matched 1-to-1 by propensity score. Matching was done by age, gender, receipt of neoadjuvant chemotherapy, preoperative hydronephrosis, variant histology, lymphovascular invasion, or carcinoma in situ on index transurethral resection of bladder tumor. RESULTS: A total of 548 patients with muscle-invasive bladder cancer were included after matching (2 groups of 274 patients). Kaplan-Meier estimates of recurrence-free and overall survival demonstrated no significant difference based upon performance of repeat transurethral resection of bladder tumor (P = 1.0 and P = .3, respectively). When outcomes were stratified by pathology of repeat transurethral resection of bladder tumor specimens, those with pT0 had superior recurrence-free and overall survival compared to those with residual muscle invasive disease (P < .001 and P = .001, respectively). Notably, more than 60% of patients who were pT0 on repeat transurethral resection of bladder tumor had residual disease at the time of radical cystectomy. CONCLUSIONS: Repeat transurethral resection of bladder tumor prior to radical cystectomy, irrespective of receipt of neoadjuvant chemotherapy, was not associated with improved survival outcomes in this propensity score matched muscle-invasive bladder cancer cohort. The absence of residual tumor on pathological evaluation of repeat transurethral resection of bladder tumor specimen was prognostic and was associated with improved survival outcomes. However, a large percentage of patients with pT0 disease on repeat transurethral resection of bladder tumor had residual disease on radical cystectomy pathology.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Bree KK, Kokorovic A, Westerman ME, et al. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy is Prognostic but Not Therapeutic. J Urol. 2022. PMID: 36250944. doi:10.1097/JU.0000000000003015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。